| ID | 119073 |
| 著者 |
板東, 浩
Medical Research|Tokushima University|Japan Low Carbohydrate Diet Promotion Association
KAKEN研究者をさがす
|
| キーワード | Triple receptor agonist
Dual receptor agonist
Incretin peptide
Glucagon-like peptide-1 (GLP-1)
Glucose-dependent insulinotropic polypeptide (GIP)
Glucagon (GCG)
Tirzepatide
|
| 資料タイプ |
学術雑誌論文
|
| 抄録 | Recent trends for the treatment of type 2 diabetes (T2D) show dual or triple receptor agonists for incretins peptides. They are glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon (GCG). Triple receptor agonist includes LY3437943, in which clinical efficacy for 12 weeks was glucose -3.1 mmol/L, HbA1c -1.6% and weight -8.96 kg. Dual agonist includes tirzepatide (GIP/GLP-1) that shows remarkable efficacy for lowering blood glucose for T2D patients. Tirzepatide (10 mg/day) showed 20% of weight reduction at 72 weeks and was also effective for heart failure with preserved ejection fraction (HFpEF), non-alcoholic steatohepatitis (NASH) and major adverse cardiovascular events (MACE).
|
| 掲載誌名 |
Journal of Diabetes, Obesity & Metabolism
|
| 出版者 | Yumed Text
|
| 巻 | 5
|
| 号 | 1
|
| 開始ページ | e109
|
| 発行日 | 2022-12-21
|
| 権利情報 | Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/)
|
| 出版社版URL | |
| フルテキストファイル | |
| 言語 |
eng
|
| 著者版フラグ |
出版社版
|
| 部局 |
医学系
|
